In a landmark decision, Canadian health authorities have approved psilocybin-assisted therapy for four palliative care patients—the first legal use of this psychedelic substance since its prohibition over 45 years ago.
Hallucinogenic or "magic" mushrooms remain prohibited for sale and consumption worldwide, including in Canada, except under special authorizations for clinical or research purposes. While often associated with recreational use, psilocybin—the key psychoactive compound—shows promise in therapeutic settings.
TheraPsil, a leading Canadian non-profit, advocates for legal access to psilocybin therapy. On August 4, 2020, the organization announced its support for applications from four patients with incurable cancer in palliative care.
After a 100-day review, Health Minister Patty Hajdu approved the requests. These patients will now receive psilocybin treatment to alleviate end-of-life distress, marking the first exemption since the substance was banned in Canada in 1974.
“I would like to thank the Minister of Health and Health Canada for approving my request to use psilocybin. Recognition of the pain and anxiety I am suffering means a lot to me, and I feel very emotional today as a result. I hope this is just the beginning and that soon all Canadians will be able to access psilocybin for therapeutic purposes to relieve the pain they are experiencing without having to petition the government for months for permission.” — Laurie Brooks, a British Columbia patient and elected official.
TheraPsil and these pioneering patients express gratitude to health authorities for this advancement, which could pave the way for broader access to psilocybin in end-of-life care. Notably, a 2011 pilot study by University of California, Los Angeles researchers involving 12 terminal cancer patients demonstrated psilocybin's potential to match or surpass conventional treatments for distress and despair. Published in Archives of General Psychiatry, the study emphasized the need for careful, controlled administration.
